261 related articles for article (PubMed ID: 22898604)
21. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Mao JH; Sun XY; Liu JX; Zhang QY; Liu P; Huang QH; Li KK; Chen Q; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21683-8. PubMed ID: 21118980
[TBL] [Abstract][Full Text] [Related]
22. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P
Haematologica; 2007 Jun; 92(6):838-41. PubMed ID: 17550858
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
Puissant A; Robert G; Fenouille N; Luciano F; Cassuto JP; Raynaud S; Auberger P
Cancer Res; 2010 Feb; 70(3):1042-52. PubMed ID: 20103647
[TBL] [Abstract][Full Text] [Related]
24. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
[TBL] [Abstract][Full Text] [Related]
25. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
26. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
Crowley LC; Elzinga BM; O'Sullivan GC; McKenna SL
Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
[TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine promotes BCR‑ABL degradation through the p62‑mediated autophagy pathway.
Li S; Bo Z; Jiang Y; Song X; Wang C; Tong Y
Oncol Rep; 2020 Jan; 43(1):113-120. PubMed ID: 31789418
[TBL] [Abstract][Full Text] [Related]
28. Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.
Song LL; Tu YY; Xia L; Wang WW; Wei W; Ma CM; Wen DH; Lei H; Xu HZ; Wu YL
PLoS One; 2014; 9(8):e104985. PubMed ID: 25115845
[TBL] [Abstract][Full Text] [Related]
29. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
30. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
[TBL] [Abstract][Full Text] [Related]
32. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
[TBL] [Abstract][Full Text] [Related]
33. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
34. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Puccetti E; Güller S; Orleth A; Brüggenolte N; Hoelzer D; Ottmann OG; Ruthardt M
Cancer Res; 2000 Jul; 60(13):3409-13. PubMed ID: 10910048
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
36. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
Dumka D; Puri P; Carayol N; Lumby C; Balachandran H; Schuster K; Verma AK; Terada LS; Platanias LC; Parmar S
Leuk Lymphoma; 2009 Dec; 50(12):2017-29. PubMed ID: 19672773
[TBL] [Abstract][Full Text] [Related]
37. Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein.
Shinohara H; Minami Y; Naoe T; Akao Y
Haematologica; 2019 May; 104(5):e191-e194. PubMed ID: 30467207
[No Abstract] [Full Text] [Related]
38. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
[TBL] [Abstract][Full Text] [Related]
39. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
Sekine Y; Ikeda O; Mizushima A; Ueno Y; Muromoto R; Yoshimura A; Kanakura Y; Oritani K; Matsuda T
Oncogene; 2012 Oct; 31(40):4384-96. PubMed ID: 22231445
[TBL] [Abstract][Full Text] [Related]
40. Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy.
Cheng J; Wei HL; Chen J; Xie B
Toxicol Mech Methods; 2012 Sep; 22(7):512-9. PubMed ID: 22519831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]